A. Roth

9.2k citations

55 papers · 4.0k indexed · 2 hit papers · h-index 28

Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis 12
Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 26
- Cancer Treatment and Pharmacology 8
Pathology and Forensic Medicine top 2%
- Genetic factors in colorectal cancer 9
Pulmonary and Respiratory Medicine top 2%
- Gastric Cancer Management and Outcomes 17
- Lung Cancer Treatments and Mutations 7
Gastroenterology top 2%
Surgery
- Cholangiocarcinoma and Gallbladder Cancer Studies 7
- Colorectal and Anal Carcinomas 6

Co-authors: Laura Rubbia‐Brandt Gilles Mentha Vincent Audard Stanislas Chaussade P. Sartoretti B. Dousset Catherine Brézault Benoît Terris
Cited by: Hepatology Oncology Pathology and Forensic Medicine
Journals: Annals of Oncology (18 papers)Journal of Clinical Oncology (11 papers)British Journal of Cancer (4 papers)
Partner nations: Switzerland United States France

In The Last Decade

A. Roth

55 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by A. Roth

Since Specialization

Citations

This map shows the geographic impact of A. Roth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Roth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Roth more than expected).

Fields of papers citing papers by A. Roth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Roth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Roth. The network helps show where A. Roth may publish in the future.

Co-authorship network

The 25 scholars most cited alongside A. Roth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with A. Roth Line = papers co-authored together A. Roth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) Annals of Oncology ·Dieter Koeberle,Jean‐François Dufour,Gyula Demeter,SU Shao-chun,Karin Ribi,Panagiotis Samaras,Piercarlo Saletti,A. Roth,Daniel Horber,M. Buehlmann,Dorothea Wagner,Michael Montemurro,Gábor Lakatos,Jonas Feilchenfeldt,Markus Peck‐Radosavljevic,Daniel Rauch,Richard A. Milliman,G. Bodoky	2016	102
2	Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor Annals of Oncology ·Gunnar Folprecht,Philip Beer,Ramón Salazar,A. Roth,Daniela E. Aust,Roberto Salgado,Pierre Laurent‐Puig,Josep Tabernero,Dirk Arnold,Alexander Stein,V. Golfinopoulos,陳詠霖,Russell G. Wilcox,Michel Ducreux,Thierry Gorlia,Sabine Tejpar	2016	1
3	Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) Annals of Oncology ·Dieter Koeberle,Daniel Betticher,Roger von Moos,D. Dietrich,Peter Brauchli,信夫下司,Daniela Frizon Alfieri,Sun Young Rha,Markus Borner,Sandro Anchisi,Peter Moosmann,Attila Kollár,Piercarlo Saletti,A. Roth,M. Frueh,Saya Matsumoto,Răzvan Popescu,Edgar Taschdjian,Viviane Hess,Richard Herrmann	2015	92
4	Is trauma in Switzerland any different? Epidemiology and patterns of injury in major trauma – a 5-year review from a Swiss trauma centre Swiss Medical Weekly ·Christine Heim,Elisabete Manuela de Sousa Ramos,A. Roth,Jocelyne Bloch,Olivier Borens,Anjas Arya Pangestu,Alban Denys,Mauro Oddo,Mathieu Pasquier,Sabine Schmidt,Patrick Schoettker,Tobias Zingg,JB Wasserfallen	2014	41
5	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical featuresbreakdown → Annals of Oncology ·Edoardo Missiaglia,Bart Jacobs,貞夫上条,Antonio Fabio Di Narzo,Charlotte Soneson,Eva Budínská,Vlad Popovici,Loredana Vecchione,Sarah Gerster,Ping Yan,A. Roth,Dirk Klingbiel,Fred T. Bosman,Mauro Delorenzi,Sabine Tejpar	2014	477
6	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial Annals of Oncology ·Dirk Klingbiel,Zacharenia Saridaki,A. Roth,Fred T. Bosman,Mauro Delorenzi,Sabine Tejpar	2014	168
7	Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer JNCI Journal of the National Cancer Institute ·A. Roth,Mauro Delorenzi,Sabine Tejpar,Ping Yan,Dirk Klingbiel,Roberto Fiocca,貞夫上条,Laura A. Cisar,Roberto Labianca,David Cunningham,Bernard Nordlinger,Fred T. Bosman,Eric Van Cutsem	2012	189
8	Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial Annals of Oncology ·A. Roth,Dirk Klingbiel,Ping Yan,Roberto Fiocca,Mauro Delorenzi,Roberto Labianca,David Cunningham,Eric Van Cutsem,Fred T. Bosman,Sabine Tejpar	2010	2
9	Molecular markers in colon cancer have a stage specific prognostic value. results of the translational study on the petacc 3-eortc 40883-sakk 60-00 trial Annals of Oncology ·A. Roth,Sabine Tejpar,Ping Yan,Roberto Fiocca,Dirk Klingbiel,Mauro Delorenzi,Damien Dietrich,Roberto Labianca,David Cunningham,Eric Van Cutsem,Fred T. Bosman	2009	7
10	Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib European Journal of Cancer ·Michael Montemurro,Patrick Schöffski,Peter Reichardt,Hans Gelderblom,J. Schütte,J.T. Hartmann,Roger von Moos,Beatrice Seddon,Heikki Joensuu,C.‐M. Wendtner,Eckhard Weber,Viktor Grünwald,A. Roth,Serge Leyvraz	2009	109
11	Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Annals of Oncology ·Markus Borner,Dieter Koeberle,Roger von Moos,Piercarlo Saletti,Daniel Rauch,Viviane Hess,Andreas Trojan,Daniel Helbling,Bernhard C. Pestalozzi,Clemens B. Caspar,Thomas Ruhstaller,A. Roth,Андреас Каппелер,Damien Dietrich,Doris Lanz,Walter Mingrone	2008	108
12	Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour European Journal of Surgical Oncology ·Gilles Mentha,Pietro Majno,Sylvain Terraz,Laura Rubbia‐Brandt,Pascal Gervaz,Axel Andrès,Abdelkarim S. Allal,P. Morel,A. Roth	2007	63
13	A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers Investigational New Drugs ·Tudor–Eliade Ciuleanu,Mircea Diculescu,N. Hoepffner,Jörg Trojan,Rebecca Alinder,Mark M. Zalupski,Thomas Herrmann,A. Roth,G.G. Baysarova,Nermin Kajtazović,Donald G. Albert,P. A. Philip	2007	6
14	Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Annals of Oncology ·Laura Rubbia‐Brandt,Emiliano Giostra,Catherine Brézault,A. Roth,Axel Andrès,Vincent Audard,P. Sartoretti,B. Dousset,Pietro Majno,Olivier Soubrane,Stanislas Chaussade,Gilles Mentha,Benoît Terris	2006	374
15	Complete Closure of Cancer-Related Anovaginal and Anoperineal Fistulas in Locally Advanced Anal Canal Carcinomas by Upfront Intra-Arterial Chemotherapy Followed by Combined Radiochemotherapy: Report of Two Cases Diseases of the Colon & Rectum ·Julie Ann. Wheeler,Abdelkarim S. Allal,P. Morel,Benjamín Roche,A. Roth	2006	3
16	Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study British Journal of Cancer ·Eric Van Cutsem,Luc Dirix,J-L. van Laethem,Simon Van Belle,Markus Borner,Manuel González Barón,A. Roth,R. Morant,E. Joosens,G. Gruia,Tom Tourw,Harry Bleiberg	2005	35
17	Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001) European Journal of Cancer ·Eric Van Cutsem,M. Dicato,J. Wils,David Cunningham,Eduardo Díaz‐Rubio,Bengt Glimelius,Daniel G. Haller,Patrick Johnston,David Kerr,Marcelly Oliveira Pinton,Roberto Labianca,Bruce D. Minsky,Bernard Nordlinger,A. Roth,P Rougier,Hans‐Joachim Schmoll	2002	45
18	Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I–II study Annals of Oncology ·A. Roth,Abdelkarim S. Allal,Marie‐Anne Bründler,R de Peyer,Bernadette Mermillod,Philippe Morel,Olivier Huber	2002	37
19	Intra-arterial chemotherapy in locally advanced or recurrent carcinomas of the penis and anal canal: an active treatment modality with curative potential British Journal of Cancer ·A. Roth,Christophe R. Berney,Lode Lauwaert,Abdelkarim S. Allal,P. Morel,Hamid Yahya Hussain,Matti Aapro,P. Alberto	2000	21
20	A patient with features of both Bardet-Biedl and Alström syndromes European Journal of Pediatrics ·Carl J. Hauser,Fitri Takribiah,A. Roth,Emily A. Schmied,J.‐H. Saurat	1990	15

About A. Roth

A. Roth is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine, having authored 55 papers that have together received 4.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (26 papers), Gastric Cancer Management and Outcomes (17 papers), Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Genetic factors in colorectal cancer (9 papers), Cancer Treatment and Pharmacology (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal and Anal Carcinomas (6 papers). The work is most often cited by research in Hepatology (1.5k citations), Oncology (2.8k citations) and Pathology and Forensic Medicine (766 citations). A. Roth has collaborated with scholars based in Switzerland, United States and France. Frequent co-authors include Laura Rubbia‐Brandt, Gilles Mentha, Vincent Audard, Stanislas Chaussade, P. Sartoretti, B. Dousset, Catherine Brézault, Benoît Terris, Olivier Soubrane and Fred T. Bosman. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer and British journal of surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact